Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Forum

    This is a preview of subscription content, log in to check access.

    References

    References

    1. 1.

      Food and Drug Administration. FDA transparency task force unveils draft proposals on agency disclosure policies [media release]. 2010 May 19 [online]. Available from URL: http://www.fda.gov [Accessed 2010 May 21]

    2. 2.

      Asamoah AK, Sharfstein JM. Transparency at the Food and Drug Administration. N Engl J Med 2010 [online]. Available from URL: http://dx.doi.org/10.1056/NEJMp1005202 [Accessed 2010 May 21]

    Reference

    1. European Medicines Agency. EMA rapped over access to adverse drug action reports [media release]. 2010 May 11 [online]. Available from URL: http://www.pharmatimes.com [Accessed 2010 May 12]

    Reference

    1. Lo J, St-Gelais F. Adverse reaction and incident reporting: 2009. Canadian Adverse Reaction Newsletter 2010; 20 (2): 2–3

    References

    1. 1.

      Feifer RA, James JM. Geographic variation in drug safety: potentially unsafe prescribing of medications and prescriber responsiveness to safety alerts. J Managed Care Pharmacy 2010; 16 (3): 196–205

    2. 2.

      Ollendorf DA. Variation in prescriber responses to drug safety alert messages: disease, symptom, or red herring? J Managed Care Pharmacy 2010; 16 (3): 231–2

    Reference

    1. CVS Caremark. CVS Caremark examining consumer mindset and why some patients stop taking their medicine [media release]. 2010 Apr 13 [online]. Available from URL: http://www.info.cvscarmark.com [Accessed 2010 Apr 21]

    Reference

    1. Frost and Sullivan. Frost & Sullivan: orphan drugs to create paradigm shift in the pharmaceutical industry [media release]. 2010 Apr 6 [online]. Available from URL: http://www.frost.com [Accessed 2010 Apr 21]

    Reference

    1. World Health Organisation. WHO adverse drug reaction database logs its 5 millionth entry [media release]. 2010 Mar 16 [online]. Available from URL: http://www.who-umc.org [Accessed 2010 Mar 18]

    Reference

    1. Companiesandmarkets.com. Belgium pharmaceuticals and healthcare report Q2 2010: report summary. 2010 Feb 22 [online]. Available from URL: http://www.companiesandmarkets.com [Accessed 2010 Mar 1]

    Reference

    1. Taylor L. Russian pharma market to grow 16% this year. 2010 Mar 22 [online]. Available from URL: http://www.pharmatimes.com [Accessed 2010 Mar 23]

    Reference

    1. Taylor L. Pharmerging nations to account for 48%of growth in 2013. 2010 Mar 17 [online]. Available from URL: http://www.pharmatimes.com [Accessed 2010 Mar 18]

    Reference

    1. Taylor L. Prescription drug use among US children soaring. 2010 May 24 [online]. Available from URL: http://www.pharmatimes.com [Accessed 2010 May 25]

    Reference

    1. Global Fund to Fight AIDS, Tuberculosis and Malaria. The Global Fund 2010: innovation and impact results summary. 2010 Mar [online]. Available from URL: http://www.theglobalfund.org [Accessed 2010 Apr 1]

    Reference

    1. Prime Therapeutics LLC. New Prime Therapeutics study bolsters evidence that extended supply improves drug adherence among chronically ill [media release]. 2010 Apr 9 [online]. Available from URL: http://www.primetherapeutics.com [Accessed 2010 Apr 12]

    Reference

    1. Taylor L. US Senate panel commences drug pricing probe. 2010 Mar 22 [online]. Available from URL: http://www.pharmatimes.com [Accessed 2010 Mar 23]

    Reference

    1. Fleurence RL, Spackman DE, Hollenbeak C. Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis. Pharmacoeconomics 2010; 28 (4): 295–306

    Reference

    1. Prime Therapeutics LLC. New study finds one in six cancer patients with high out-of-pocket costs not filling prescriptions [media release]. 2010 Apr 9 [online]. Available from URL: http://www.primetherapeutics.com [Accessed 2010 Apr 12]

    References

    1. 1.

      Nissen SE. Setting the RECORD straight. JAMA 2010; 303 (12): 1194–5 [online]. Available from URL: http://dx.doi.org/10.1001/jama.2010.333 [Accessed 2010 Mar 29]

    2. 2.

      DeAngelis CD, Fontanarosa PB. Ensuring integrity in industrysponsored research: primum non nocere, revisited. JAMA 2010; 303 (12): 1194–5 [online]. Available from URL: http://dx.doi.org/10.1001/jama.2010.337 [Accessed 2010 Mar 29]

    Reference

    1. Santiago F, Goncalo M, Vieira R, et al. Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermatitis 2010; 62 (1): 47–53

    Reference

    1. Gruber J. The cost implications of health care reform. N Engl J Med 2010 [online]. Available from URL: http://dx.doi.org/10.1056/nejmp1005117 [Accessed 2010 May 17]

    Reference

    1. Pharmaceutical Research and Manufacturers of America. New report shows major diseases being addressed with over 230 medicines in development for children [media release]. 2010 Mar 30 [online]. Available from URL: http://www.phrma.org [Accessed 2010 Apr 6]

    References

    1. 1.

      Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010; 303 (14): 1401–9

    2. 2.

      Schneeweiss S, Patrick AR, Solomon DH, et al. Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts. Pediatrics 2010; 125 (5): 876–88

    Reference

    1. Milliman Inc. New diabetes study breaks down economic burden of uncontrolled diabetes [media release]. 2010 Apr 28 [online]. Available from URL: http://www.milliman.com [Accessed 2010 Apr 29]

    Reference

    1. Stafford N. At least 25% of elderly residents of German nursing homes are addicted to psychotropic drugs, report claims. BMJ 2010 [online]. Available from URL: http://www.bmj.com/cgi/content/full/340/apr13_3/c2029 [Accessed 2010 May 1]

    References

    1. 1.

      Katz MH. Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med 2010; 170 (9): 747–8

    2. 2.

      Gray SL, Lacroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med 2010; 170 (9): 765–71

    3. 3.

      Corley DA, Kubo A, Zhao W, et al. Proton pump inhibitors and histamine- 2 receptor antagonists are associated with hip fractures among atrisk patients. Gastroenterology. Epub 2010 Mar 27

    4. 4.

      Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010; 170 (9): 772–8

    5. 5.

      Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170 (9): 784–90

    Reference

    1. Curhan SG, Eavey R, Shargorodsky J, et al. Analgesic use and the risk of hearing loss in men. Am Med 2010; 123 (3): 231–7

    Reference

    1. Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics. Epub 2010 Feb 22

    Reference

    1. Trifiro G, Gambassi G, Sen EF, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested casecontrol study. Ann Intern Med 2010; 152 (7): 418–25

    Reference

    1. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. Epub 2010 Mar 24

    Reference

    1. Food and Drug Administration. FDA drug safety communication: ongoing safety review of GnRH agonists and possible increased risk of diabetes and certain cardiovascular diseases. 2010 Mar 5 [online]. Available from URL: http://www.fda.gov [Accessed 2010 Mar 8]

    References

    1. 1.

      Clifford DB, DeLuca A, Simpson D, et al. Progressive multifocal leukoencephalopathy with natalizumab treatment of multiple sclerosis [abstract no. PL01.003]. 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10–17; Toronto (ON)

    2. 2.

      Frenay CL, Debouverie M, Brassat D, et al. Cancer risk among patients with multiple sclerosis during the treatment era: the CARIMS study update [abstract no. P06.135]. 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10–17; Toronto (ON)

    3. 3.

      Savettieri G, Aridon P, D’Amelio M, et al. Frequency of mitoxantrone related heart involvement in patients affected by multiple sclerosis [abstract no. P06.140]. 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10–17; Toronto (ON)

    4. 4.

      Ionete C, Ebuh V, Singh A, et al. Central demyelination complicating the use of anti-TNFα in the treatment of inflammatory bowel disease (IBD): a retrospective study [abstract no. P06.166]. 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10–17; Toronto (ON)

    5. 5.

      Rocher F, Laffon M, Cohen M, et al. Hypereosinophilia with natalizumab [abstract no. P04.194]. 62nd Annual Meeting of theAmerican Academy of Neurology; 2010 Apr 10–17; Toronto (ON)

    6. 6.

      Hutton GJ, Avila M, Prieto PG, et al. Multiple sclerosis and other CNS demyelination after treatment with tumor necrosis factor alpha blockers [abstract no. P04.215]. 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10–17; Toronto (ON)

    7. 7.

      Al-Sabbagh A, Dawson D, Bennett R, et al. Acute leukemia in multiple sclerosis patients treated with mitoxantrone in the postmarketing setting: the EMD Serono experience [abstract no. P01.170]. 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10–17; Toronto (ON)

    8. 8.

      Dangond F, Dawson D, Beagan J, et al. Cardiovascular adverse events with mitoxantrone: results from the registry to evaluate novantrone effects inworsening multiple sclerosis (RENEW) study. 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10–17; Toronto (ON)

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Forum. Pharm Med 24, 179–190 (2010). https://doi.org/10.1007/BF03256814

    Download citation